<- Go Home
Protagenic Therapeutics, Inc.
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
Market Cap
$3.2M
Volume
70.1K
Cash and Equivalents
$1.1M
EBITDA
-$5.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$1.87
52 Week Low
$0.46
Dividend
N/A
Price / Book Value
3.14
Price / Earnings
-0.37
Price / Tangible Book Value
3.14
Enterprise Value
$2.1M
Enterprise Value / EBITDA
-0.41
Operating Income
-$5.3M
Return on Equity
231.87%
Return on Assets
-94.91
Cash and Short Term Investments
$1.1M
Debt
N/A
Equity
$719.0K
Revenue
N/A
Unlevered FCF
-$2.8M
Sector
Biotechnology
Category
N/A